MBX Biosciences (MBX) Operating Leases (2023 - 2026)

MBX Biosciences has reported Operating Leases for 4 years, with the latest figure at $377000.0 in Q1 2026.

• Quarterly Operating Leases changed N/A year-over-year to $377000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $377000.0 (changed N/A YoY) and the FY2025 annual result came in at $424000.0, changed N/A from the prior year.
• Operating Leases declined to $377000.0 in Q1 2026 per MBX's latest filing, from $424000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $512000.0 in Q2 2025 and troughed at $44000.0 in Q3 2024.
• A 4-year average of $332833.3 and a median of $400500.0 in 2025 frame the typical range for Operating Leases.
• The widest YoY moves for Operating Leases: up 965.91% in 2025, down 965.91% in 2025.
• Over 4 years, Operating Leases stood at $171000.0 in 2023, then tumbled by 74.27% to $44000.0 in 2024, then soared by 863.64% to $424000.0 in 2025, then fell by 11.08% to $377000.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $377000.0, $424000.0, and $469000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.